Free Trial

Neurocrine Biosciences (NBIX) Competitors

Neurocrine Biosciences logo
$121.02 +0.75 (+0.62%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$116.10 -4.91 (-4.06%)
As of 05/16/2025 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NBIX vs. ALNY, BIIB, UTHR, INCY, BMRN, EXEL, EXAS, HALO, RGEN, and MDGL

Should you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.

Neurocrine Biosciences vs.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Alnylam Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

Neurocrine Biosciences has a net margin of 14.49% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Neurocrine Biosciences' return on equity of 13.38% beat Alnylam Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals-12.37% N/A -6.83%
Neurocrine Biosciences 14.49%13.38%9.73%

Alnylam Pharmaceuticals received 123 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.68% of users gave Neurocrine Biosciences an outperform vote while only 76.32% of users gave Alnylam Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Alnylam PharmaceuticalsOutperform Votes
1167
76.32%
Underperform Votes
362
23.68%
Neurocrine BiosciencesOutperform Votes
1044
77.68%
Underperform Votes
300
22.32%

In the previous week, Neurocrine Biosciences had 9 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for Neurocrine Biosciences and 20 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.21 beat Neurocrine Biosciences' score of 1.13 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
13 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Neurocrine Biosciences
18 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$2.35B15.84-$278.16M-$2.09-136.51
Neurocrine Biosciences$2.41B4.96$341.30M$2.9541.02

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alnylam Pharmaceuticals currently has a consensus price target of $319.17, suggesting a potential upside of 11.87%. Neurocrine Biosciences has a consensus price target of $162.00, suggesting a potential upside of 33.86%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
1 Sell rating(s)
4 Hold rating(s)
21 Buy rating(s)
0 Strong Buy rating(s)
2.77
Neurocrine Biosciences
0 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

Summary

Neurocrine Biosciences beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks.

Get Neurocrine Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NBIX vs. The Competition

MetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$11.98B$2.88B$5.36B$8.52B
Dividend YieldN/A1.94%4.95%4.12%
P/E Ratio36.7830.7327.0220.02
Price / Sales4.96408.24390.42119.66
Price / Cash34.35168.6838.2534.62
Price / Book4.663.066.764.60
Net Income$341.30M-$72.35M$3.23B$248.70M
7 Day Performance4.59%3.92%4.85%5.15%
1 Month Performance19.37%8.37%9.89%13.70%
1 Year Performance-14.95%-28.71%14.87%6.80%

Neurocrine Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBIX
Neurocrine Biosciences
4.949 of 5 stars
$121.02
+0.6%
$162.00
+33.9%
-14.7%$11.98B$2.41B36.781,200Trending News
ALNY
Alnylam Pharmaceuticals
4.2998 of 5 stars
$270.19
+7.6%
$319.17
+18.1%
+88.7%$35.23B$2.35B-124.512,000Trending News
BIIB
Biogen
4.922 of 5 stars
$124.40
+5.3%
$191.30
+53.8%
-45.4%$18.23B$9.82B11.128,720Trending News
Analyst Revision
UTHR
United Therapeutics
4.9925 of 5 stars
$310.80
+3.1%
$392.00
+26.1%
+12.2%$14.02B$2.99B13.65980Trending News
INCY
Incyte
4.8965 of 5 stars
$60.85
+3.2%
$73.53
+20.8%
+11.3%$11.78B$4.41B225.382,320Trending News
BMRN
BioMarin Pharmaceutical
4.9947 of 5 stars
$61.37
+4.3%
$93.45
+52.3%
-23.0%$11.77B$2.95B27.903,080Trending News
EXEL
Exelixis
4.0857 of 5 stars
$36.98
+2.2%
$37.59
+1.6%
+113.8%$10.19B$2.17B20.891,220Trending News
Analyst Forecast
Insider Trade
Options Volume
EXAS
Exact Sciences
4.7029 of 5 stars
$53.40
+3.4%
$70.90
+32.8%
+8.6%$10.07B$2.83B-9.596,400Positive News
HALO
Halozyme Therapeutics
4.8784 of 5 stars
$66.58
+1.1%
$63.78
-4.2%
+14.6%$8.20B$1.08B19.41390Analyst Downgrade
RGEN
Repligen
4.9048 of 5 stars
$133.72
+8.5%
$173.25
+29.6%
-26.0%$7.51B$650.43M-262.202,020Positive News
Gap Up
MDGL
Madrigal Pharmaceuticals
4.6451 of 5 stars
$300.76
+2.1%
$416.33
+38.4%
+34.0%$6.68B$317.38M-11.9990Positive News

Related Companies and Tools


This page (NASDAQ:NBIX) was last updated on 5/17/2025 by MarketBeat.com Staff
From Our Partners